ImmunXperts brings proven expertise in helping clients assess the immuno-functionality of lead candidates in immuno-oncology, auto-immunity, infection/inflammation, and cell and gene therapy. We help clients assess functionality and reduce risk prior to first-in-human administration. ImmunXperts has assisted drug developers in screening and selecting a wide range of promising candidates, including PD-1/PDL-1 and a wide range of first- and second-generation immune checkpoint inhibitors, advancing approximately 150 programs a year to the next phase of development.
T-cell Assays
Myeloid Cell Assays
Killing Assays
Neutrophil Activation Assays
DC Assays